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A bs t r ac t
Background

The benefits of endoscopic testing for colorectal-cancer screening are uncertain. We
evaluated the effect of screening with flexible sigmoidoscopy on colorectal-cancer
incidence and mortality.
Methods

From 1993 through 2001, we randomly assigned 154,900 men and women 55 to 74
years of age either to screening with flexible sigmoidoscopy, with a repeat screening
at 3 or 5 years, or to usual care. Cases of colorectal cancer and deaths from the disease
were ascertained.
Results

Of the 77,445 participants randomly assigned to screening (intervention group), 83.5%
underwent baseline flexible sigmoidoscopy and 54.0% were screened at 3 or 5 years.
The incidence of colorectal cancer after a median follow-up of 11.9 years was 11.9
cases per 10,000 person-years in the intervention group (1012 cases), as compared
with 15.2 cases per 10,000 person-years in the usual-care group (1287 cases), which
represents a 21% reduction (relative risk, 0.79; 95% confidence interval [CI], 0.72 to
0.85; P<0.001). Significant reductions were observed in the incidence of both distal
colorectal cancer (479 cases in the intervention group vs. 669 cases in the usual-care
group; relative risk, 0.71; 95% CI, 0.64 to 0.80; P<0.001) and proximal colorectal cancer (512 cases vs. 595 cases; relative risk, 0.86; 95% CI, 0.76 to 0.97; P = 0.01). There
were 2.9 deaths from colorectal cancer per 10,000 person-years in the intervention
group (252 deaths), as compared with 3.9 per 10,000 person-years in the usual-care
group (341 deaths), which represents a 26% reduction (relative risk, 0.74; 95% CI,
0.63 to 0.87; P<0.001). Mortality from distal colorectal cancer was reduced by 50%
(87 deaths in the intervention group vs. 175 in the usual-care group; relative risk, 0.50;
95% CI, 0.38 to 0.64; P<0.001); mortality from proximal colorectal cancer was unaffected (143 and 147 deaths, respectively; relative risk, 0.97; 95% CI, 0.77 to 1.22; P = 0.81).

The authors’ affiliations are listed in the
Appendix. Address reprint requests to Dr.
Schoen at the Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh Medical Center, Mezzanine Level, C Wing, PUH, 200 Lothrop St.,
Pittsburgh, PA 15213-2582, or at rschoen@
pitt.edu.
* Members of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial project team are listed in the
Supplementary Appendix, available at
NEJM.org.
This article (10.1056/NEJMoa1114635) was
published on May 21, 2012, at NEJM.org.
N Engl J Med 2012;366:2345-57.
Copyright © 2012 Massachusetts Medical Society.

Conclusions

Screening with flexible sigmoidoscopy was associated with a significant decrease in
colorectal-cancer incidence (in both the distal and proximal colon) and mortality
(distal colon only). (Funded by the National Cancer Institute; PLCO ClinicalTrials.gov
number, NCT00002540.)
n engl j med 366;25
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olorectal cancer is the second
leading cause of cancer-related deaths in
the United States.1 Colorectal-cancer mor2-4
tality and incidence5,6 are reduced with screening by means of fecal occult-blood testing. Endoscopic screening with flexible sigmoidoscopy or
colonoscopy is more sensitive than fecal testing for
the detection of adenomatous polyps, the precursor
lesions of colorectal cancer.7-9 Three European
randomized trials of flexible sigmoidoscopy have
been performed.10 In the United Kingdom, onetime screening with flexible sigmoidoscopy significantly reduced the incidence of colorectal cancer
(by 23%) and associated mortality (by 31%).11 In
Italy, an 18% reduction in incidence and a nonsignificant 22% reduction in mortality were observed,12 whereas in Norway, no benefit was observed after 7 years of follow-up.13
In the United States, the multicenter, randomized Prostate, Lung, Colorectal, and Ovarian
(PLCO) Cancer Screening Trial evaluated flexible
sigmoidoscopy in comparison with usual care. Two
screenings with flexible sigmoidoscopy were offered, 3 or 5 years apart. Previous reports have
described the outcome from the first screening10
and the yield from both screenings.14 We report
here on the effect of screening flexible sigmoidoscopy on the incidence of distal and proximal
colorectal cancer and related mortality.

Me thods
Study Design

A total of 154,900 men and women 55 to 74 years
of age were enrolled from 1993 through 2001; they
provided written informed consent and completed
baseline questionnaires. The primary exclusion criteria were a history of prostate, lung, colorectal, or
ovarian cancer; ongoing treatment for any type of
cancer except basal-cell or squamous-cell skin
cancer; and, beginning in 1995, assessment by
means of a lower endoscopic procedure (flexible
sigmoidoscopy, colonoscopy, or barium enema examination) in the previous 3 years. Further details,
including data on recruitment through mass mailing, have been reported previously.15,16 Randomization was performed in blocks stratified according
to screening center, age, and sex. The study was
sponsored by the National Cancer Institute. All the
authors vouch for the accuracy of the data and the
fidelity of the study to the protocol. The protocol
and statistical analysis plan are available with the
full text of this article at NEJM.org.
2346
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Participants in the intervention group were
offered flexible sigmoidoscopy at baseline and at
3 years (for those who underwent randomization
before April 1995) or at 5 years. Repeat screening
in persons who received a diagnosis of colorectal
cancer or adenoma after the initial screening was
discouraged but did occur14 (see Fig. S1 in the
Supplementary Appendix, available at NEJM.org).
Physicians and nurse examiners followed standardized procedures for flexible sigmoidoscopic
examinations. An examination was considered to
be positive if a polyp or mass was detected. Biopsies were not routinely performed. Participants
were referred to their primary care physicians for
decisions regarding diagnostic follow-up. Medical
records related to follow-up, a diagnosis of cancer,
and cancer complications were collected.
Death from colorectal cancer was the primary
end point. Secondary end points included colorectal-cancer incidence, cancer stage, survival, harms
of screening, and all-cause mortality. All cancers
and deaths were ascertained primarily by means of
a mailed Annual Study Update questionnaire. Participants who did not return questionnaires were
contacted by repeat mailing or telephone. Cancer
incidence, stage, and location were verified from
medical records.17 Information on vital status was
supplemented by periodic linkage to the National
Death Index. Deaths that were potentially related
to prostate, lung, colorectal, or ovarian cancer were
reviewed in a blinded fashion, in an end-point
adjudication process.18 Colorectal-cancer deaths
included deaths due to colorectal cancer and those
due to its treatment. Carcinoid tumors were included as colorectal-cancer cases. Cancers located
in the rectum through the splenic flexure were
defined as distal, and those in the transverse
colon through the cecum were defined as proximal. A screening-detected cancer was defined as
a colorectal cancer diagnosed within 1 year after a
positive flexible sigmoidoscopic examination.
Assessment of Study-Group Contamination

Colorectal screening with flexible sigmoidoscopy
or colonoscopy outside the study protocol, performed for routine care (contamination), was assessed with the use of biennially and, later, annually administered health-status questionnaires. In
total, 13,788 randomly selected participants (10,077
in the usual-care group and 3711 in the intervention group) were included in the analysis. Verification of reported procedures was not obtained. To
estimate contamination in the usual-care group
nejm.org
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during the screening phase (study years 0 through
5), we determined the proportion of participants at
study years 5 and 6 who reported having undergone
routine endoscopic testing in the previous 5 years.
Contamination by colonoscopy in the intervention
group during the screening phase was defined as
routine colonoscopy in participants without a positive flexible sigmoidoscopic examination and was
estimated from reports on colonoscopy in a subgroup of 1392 participants in the intervention
group.19,20 To estimate use of colonoscopy after the
screening phase, we determined the proportion of
participants in each group in study years 11 through
13 who reported having undergone routine colonoscopic testing in the previous 5 years.

cacy and futility. We assessed the between-group
difference in mortality with the use of a weighted
log-rank test, incorporating increasing weights
that were proportional to the pooled mortality.
The weighted statistic was chosen because of the
presumed delay in the effect of screening on
colorectal-cancer mortality. The monitoring design
stipulated a one-sided efficacy boundary, constructed by means of the Lan–DeMets procedure
with an O’Brien–Fleming spending function,23 and
a nonbinding futility boundary was constructed
with the use of stochastic curtailment24 (see the
Supplementary Appendix). All analyses were performed with SAS/STAT software, version 9 (SAS
Institute),25 or R software, version 2.12.0 (R Development Core Team).26

Statistical Analysis

The primary analysis was an intention-to-screen
comparison of colorectal-cancer mortality between
the study groups. Event rates were defined as the
number of events (cancers or deaths) divided by
person-years. For mortality, person-years were
measured from randomization to the date of death
or the date of last follow-up (censoring date), and
for incidence, person-years were measured from
randomization to the date of diagnosis, death, or
censoring, whichever came first. Data were censored on December 31, 2009, or at 13 years from
randomization, whichever came first.
The trial was designed to have 90% power to
detect a 15% or greater relative reduction in
colorectal-cancer mortality in the intervention
group, as compared with the usual-care group, on
the assumption of at least 85% compliance with
screening in the intervention group and no more
than 15% contamination among participants in
the usual-care group.15
We calculated the pointwise confidence intervals for incidence-rate and mortality ratios assuming a Poisson distribution for the number of events
and, through asymptotic methods, a normal distribution for the logarithm of the ratio.21 The number needed to invite for screening to prevent one
colorectal-cancer death or case was defined as the
number of intervention-group participants divided
by the difference in colorectal-cancer deaths or
cases between groups. The adjusted, sequential
P value and confidence interval for the colorectalcancer mortality ratio were derived in accordance
with the sequential design and the weighted
method used to monitor the trial, which allows for
a varying rate ratio.22 An interim analysis plan was
used to monitor the primary end point for effin engl j med 366;25

R e sult s
Characteristics of the Participants and Use
of Screening

A total of 77,445 participants were randomly assigned to flexible sigmoidoscopy, and 77,455 to
usual care. The baseline characteristics of the participants were similar in the two study groups (Table 1); the median follow-up time was 11.9 years,
and the mean follow-up time was 11.0 years. Vital
status within a year after the data-cutoff date was
known for 99.9% of participants, and compliance
with the Annual Study Update questionnaire was
93.8%. Randomization and follow-up are shown
in Figure S1 in the Supplementary Appendix.
In the intervention group, 83.5% of the participants (64,653) underwent baseline screening and
54.0% (41,858) underwent subsequent screening. A
total of 86.6% of participants (67,071) underwent
at least one flexible sigmoidoscopic screening, and
50.9% (39,440) underwent two screenings; in
28.5% of participants (22,083), at least one screening was positive for a polyp or mass. Of participants with abnormal screening results, 80.5% underwent a diagnostic intervention within 1 year,
95.6% of whom underwent colonoscopy; the rate
of colonoscopy performed as a direct effect of
screening with flexible sigmoidoscopy was 21.9%.
Colorectal-Cancer Incidence and Mortality
According to Study Group

Table 2 shows colorectal-cancer incidence and mortality in the intervention group as compared with
the usual-care group. The incidence of colorectal
cancer was 11.9 cases per 10,000 person-years in
the intervention group (1012 cases), as compared
nejm.org
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with 15.2 cases per 10,000 person-years in the
usual-care group (1287 cases), which represents a
21% reduction (relative risk, 0.79; 95% confidence
interval [CI], 0.72 to 0.85; P<0.001). Significant
reductions were observed in the incidence of both
distal colorectal cancer (479 cases in the intervention group vs. 669 cases in the usual-care group;
relative risk, 0.71; 95% CI, 0.64 to 0.80; P<0.001)
and proximal colorectal cancer (512 cases vs. 595
cases; relative risk, 0.86; 95% CI, 0.76 to 0.97;

of
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P = 0.01). The relative risk of colorectal cancer
among men was 0.73 (95% CI, 0.66 to 0.82) and
among women 0.86 (95% CI, 0.76 to 0.98), with a
borderline significant interaction between sex and
study-group assignment (P = 0.052). The reduction
in the incidence of colorectal cancer was similar
for participants 55 to 64 years of age (518 cases
vs. 662 cases; relative risk, 0.78; 95% CI, 0.69 to
0.87) and for those 65 to 74 years of age (494 cases
vs. 625 cases, relative risk, 0.79; 95% CI, 0.71 to

Table 1. Characteristics of the Study Participants.*
Flexible-Sigmoidoscopy Group
(N = 77,445)

Characteristic

Usual-Care Group
(N = 77,455)

no. of participants (%)
Sex
Female

39,105 (50.5)

39,111 (50.5)

Male

38,340 (49.5)

38,344 (49.5)

55–59 yr

25,851 (33.4)

25,839 (33.4)

60–64 yr

23,783 (30.7)

23,771 (30.7)

Age

65–69 yr

17,457 (22.5)

17,473 (22.6)

70–74 yr

10,354 (13.4)

10,372 (13.4)

White (non-Hispanic)

66,874 (86.4)

65,708 (84.8)

Black (non-Hispanic)

3,883 (5.0)

3,825 (4.9)

Race or ethnic group†

Hispanic

1,421 (1.8)

1,397 (1.8)

Asian

2,791 (3.6)

2,785 (3.6)

Other or unknown

2,476 (3.2)

3,740 (4.8)

High-school graduate or less

22,892 (29.6)

22,583 (29.2)

Some college

25,935 (33.5)

25,585 (33.0)

College graduate

26,659 (34.4)

25,915 (33.5)

1,959 (2.5)

3,372 (4.4)

Yes

29,244 (37.8)

29,890 (38.6)§

No

43,858 (56.6)

42,223 (54.5)

4,343 (5.6)

5,342 (6.9)

Educational level

Unknown
Prior FOBT‡

Unknown
Prior lower GI endoscopy¶
Yes

9,736 (12.6)

10,113 (13.1)§

No

64,653 (83.5)

62,997 (81.3)

3,056 (3.9)

4,345 (5.6)

Yes

31,511 (40.7)

31,990 (41.3)§

No

40,648 (52.5)

39,161 (50.6)

5,286 (6.8)

6,304 (8.1)

Unknown
Either prior FOBT or prior lower GI endoscopy

Unknown

2348
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Table 1. (Continued.)
Flexible-Sigmoidoscopy Group
(N = 77,445)

Characteristic

Usual-Care Group
(N = 77,455)

no. of participants (%)
First-degree relative with colorectal cancer
Yes

7,643 (9.9)

7,322 (9.5)

No

65,299 (84.3)

64,506 (83.3)

4,503 (5.8)

5,627 (7.3)

Yes

24,822 (32.1)

23,949 (30.9)‖

No

50,368 (65.0)

49,766 (64.3)

2,255 (2.9)

3,740 (4.8)

Unknown
Daily use of aspirin or ibuprofen in past 12 mo

Unknown
Aspirin or ibuprofen use ≥3–4 times per wk in past 12 mo
Yes

33,248 (42.9)

32,087 (41.4)**

No

41,971 (54.2)

41,658 (53.8)

2,226 (2.9)

3,710 (4.8)

Unknown

*		 There were no significant differences between the groups except as noted. FOBT denotes fecal occult-blood test, and
GI gastrointestinal.
†		 Race or ethnic group was determined by self-report.
‡		 Prior FOBT indicates a test within 3 years before study entry.
§		 P<0.001
¶		 Prior lower GI endoscopy indicates sigmoidoscopy, colonoscopy, or barium enema examination within 3 years before
randomization.
‖		 P = 0.03
** P = 0.01

0.89). The number needed to invite for screening in
order to prevent 1 case of colorectal cancer was
282 (95% CI, 210 to 427).
Mortality related to colorectal cancer was 2.9
per 10,000 person-years in the intervention group
(252 deaths), as compared with 3.9 per 10,000
person-years in the usual-care group (341 deaths),
which represents a 26% reduction (relative risk,
0.74; 95% CI, 0.63 to 0.87; P<0.001). Mortality
related to distal colorectal cancer was reduced by
50% (87 deaths in the intervention group vs. 175
in the usual-care group; relative risk, 0.50; 95%
CI, 0.38 to 0.64; P<0.001), but mortality related
to proximal colorectal cancer (143 vs. 147 deaths,
respectively; relative risk, 0.97; 95% CI, 0.77 to
1.22; P = 0.81) was unaffected. Men had a 34%
reduction in colorectal cancer mortality (139 vs.
211 deaths; relative risk, 0.66; 95% CI, 0.53 to
0.81) and women a 13% reduction (113 vs. 130
deaths; relative risk, 0.87; 95% CI, 0.68 to 1.12);
the interaction between sex and study-group assignment was not significant (P = 0.10). The relative
risks for colorectal-cancer mortality among par-

n engl j med 366;25

ticipants 55 to 64 years of age and 65 to 74 years
of age were 0.84 (95% CI, 0.67 to 1.06) and 0.65
(95% CI, 0.52 to 0.82), respectively (P = 0.11 for the
interaction between age and study-group assignment). The number needed to invite for screening
in order to prevent 1 colorectal-cancer death was
871 (95% CI, 567 to 1874).
The cumulative incidences of overall and distal
colorectal cancer were higher in the intervention
group through approximately 3 years, after which
cumulative incidences became lower in the intervention group (Fig. 1A and 1C). The cumulative
incidences of proximal colorectal cancer (Fig. 1E)
were similar for the first few years but became and
remained lower after year 3 in the intervention
group. Overall colorectal-cancer mortality and
mortality related to distal and to proximal colorectal cancer are shown in Figure 1B, 1D, and 1F.
Between-group differences in mortality emerged
within a few years and persist for total and distal colorectal cancer, but no difference in mortality related to proximal colorectal cancer was
observed.
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Table 2. Colorectal-Cancer Incidence and Mortality.*
Flexible-Sigmoidoscopy Group
(N = 77,445)

Variable

Usual-Care Group
(N = 77,455)

Relative Risk
(95% CI)

P Value

no. of
participants

rate per 10,000
person-yr
(95% CI)

no. of
participants

rate per 10,000
person-yr
(95% CI)

1012

11.9 (11.2–12.7)

1287

15.2 (14.4–16.0)

0.79 (0.72–0.85)

<0.001

Distal

479

5.6 (5.1–6.2)

669

7.9 (7.3–8.5)

0.71 (0.64–0.80)

<0.001

Proximal

512

6.0 (5.5–6.6)

595

7.0 (6.5–7.6)

0.86 (0.76–0.97)

0.01

Male

567

13.6 (12.4–14.7)

768

18.5 (17.2–19.9)

0.73 (0.66–0.82)

<0.001

Female

445

10.3 (9.4–11.3)

519

12.0 (11.0–13.0)

0.86 (0.76–0.98)

0.02

Incidence
All colorectal cancers
Location of cancer†

Sex

Age at randomization
55–64 yr

518

9.4 (8.6–10.2)

662

12.1 (11.2–13.0)

0.78 (0.69–0.87)

<0.001

65–74 yr

494

16.6 (15.1–18.1)

625

20.9 (19.3–22.5)

0.79 (0.71–0.89)

<0.001

252

2.9 (2.5–3.2)

341

3.9 (3.5–4.3)

0.74 (0.63–0.87)

<0.001

Mortality
All colorectal-cancer deaths
Location of cancer†
Distal

87

1.0 (0.8–1.2)

175

2.0 (1.7–2.3)

0.50 (0.38–0.64)

<0.001

Proximal

143

1.6 (1.4–1.9)

147

1.7 (1.4–2.0)

0.97 (0.77–1.22)

0.81

Male

139

3.2 (2.7–3.8)

211

4.9 (4.3–5.6)

0.66 (0.53–0.81)

<0.001

Female

113

2.6 (2.1–3.0)

130

2.9 (2.4–3.4)

0.87 (0.68–1.12)

0.28

55–64 yr

133

2.4 (2.0–2.8)

157

2.8 (2.3–3.2)

0.84 (0.67–1.06)

0.16

65–74 yr

119

3.9 (3.2–4.6)

184

6.0 (5.1–6.9)

0.65 (0.52–0.82)

<0.001

Sex

Age at randomization

* The median follow-up time for incidence was 11.9 years (interquartile range, 10.2 to 13.0) and for mortality was 12.1 years (interquartile
range, 10.4 to 13.0).
† Distal location was defined as the rectum through the splenic flexure, and proximal as the transverse colon through the cecum. For incidence, the location was unknown for 21 cases in the flexible-sigmoidoscopy group and 23 cases in the usual-care group. For mortality, the
location was unknown for 22 deaths in the flexible-sigmoidoscopy group and 19 deaths in the usual-care group.

Incidence and Stage of Cancer According to
Means of Detection

Table 3 shows colorectal-cancer incidence and stage
according to the means of detection. Screeningdetected cancers accounted for 24.1% of colorectal
cancers (244 of 1012) in the intervention group.
Among participants with screening-detected cancers, 82.8% of the cancers were distal, whereas
among participants who were never screened,
52.8% were distal, and among participants with
cancers not detected by screening, 31.6% were distal (P<0.001). Participants with screening-detected
cancers were more likely to have early-stage cancer
(stage I or II) than participants who were never
screened or those whose tumors were not detected
2350
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by screening (75.4% vs. 50.9% and 50.7%, respectively; P<0.001 for both comparisons).
Incidence and Mortality According to
Location and Stage of Cancer

Table 4 shows colorectal-cancer incidence and mortality according to the location in the colon and the
stage at diagnosis. Case fatality rates for stage I, II,
III, and IV cancers were similar in the intervention
and usual-care groups and were approximately 6%,
11%, 30%, and 79%, respectively. There was a reduction in the incidence of distal colorectal cancer
in the intervention group for each cancer stage,
ranging from 19.8% for stage I cancers (50 fewer
cases) to 61.7% for stage IV cancers (66 fewer casnejm.org
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A Overall Colorectal-Cancer Incidence

B Overall Colorectal-Cancer Mortality
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Figure 1. Overall, Distal, and Proximal Colorectal-Cancer Incidence and Mortality.
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Table 3. Colorectal-Cancer Incidence and Stage According to Means of Detection.
Flexible-Sigmoidoscopy Group
(N = 77,445)
Variable

All colorectal
cancers

Screening-Detected Cancer

Usual-Care Group
(N = 77,455)

Non–Screening-Detected Cancer

no. at
baseline

no. at
yr 3 or 5

total no. (%)

192

52

244 (100.0)

Total

In Screened
Participants*

In Unscreened
Participants†

607 (100.0)

161 (100.0)

1012 (100.0)

Total

number (percent)
1287 (100.0)

Location
Distal

165

37

202 (82.8)

192 (31.6)

85 (52.8)

479 (47.3)

669 (52.0)

Proximal

26

15

41 (16.8)

403 (66.4)

68 (42.2)

512 (50.6)

595 (46.2)

Unknown

1

0

1 (0.4)

12 (2.0)

8 (5.0)

21 (2.1)

23 (1.8)

136

33

169 (69.3)

324 (53.4)

74 (46.0)

567 (56.0)

768 (59.7)

56

19

75 (30.7)

283 (46.6)

87 (54.0)

445 (44.0)

519 (40.3)

I

113

33

146 (59.8)

148 (24.4)

40 (24.8)

334 (33.0)

407 (31.6)

II

31

7

38 (15.6)

160 (26.4)

42 (26.1)

240 (23.7)

309 (24.0)

III

24

6

30 (12.3)

168 (27.7)

43 (26.7)

241 (23.8)

328 (25.5)

IV

5

3

8 (3.3)

107 (17.6)

25 (15.5)

140 (13.8)

209 (16.2)

Carcinoid

17

3

20 (8.2)

10 (1.6)

2 (1.2)

32 (3.2)

9 (0.7)

Unknown

2

0

2 (0.8)

14 (2.3)

9 (5.6)

25 (2.5)

25 (1.9)

Sex
Male
Female
Stage

* This category includes participants who underwent at least one screening flexible sigmoidoscopic examination and who had cancers that
were detected because of symptoms, detected by screening performed outside the study protocol, or detected more than 1 year after a positive screening examination.
† This category includes participants who did not undergo a screening flexible sigmoidoscopic examination and who had cancers that were
detected because of symptoms or detected by screening performed outside the study protocol.

es). Mortality related to distal colorectal cancer was
also reduced for each stage, by 21.4% for stage I
cancers (3 fewer deaths) to 60.7% for stage IV cancers (51 fewer deaths). The incidence of cancer in
the proximal colon was reduced by 14.4 to 20.7%
in the intervention group for stage I, II, and III
cancers (22, 34, and 25 fewer cases, respectively)
but by only 2.0% (2 fewer cases) for stage IV disease. The number of deaths from proximal colorectal cancer was similar in the two groups. Overall,
there were only 4 fewer deaths from proximal
colorectal cancer in the intervention group. Because
of the relative paucity of cancers in the descending
colon and splenic flexure (Table S2 in the Supplementary Appendix), limiting the definition of
distal cancer to cancers in the rectum and sigmoid had little effect on the incidence or mortality results.
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Cancer Treatment, Screening Complications
and False Positive Results, and Deaths
from Other Causes

The rates of administered treatment for colorectal cancer with surgery, chemotherapy, or radiation therapy were similar overall and according to
cancer stage in the two groups (Table S1 in the
Supplementary Appendix).
There were 3 bowel perforations, 2 by the same
operator, in 107,236 flexible sigmoidoscopic examinations (2.8 per 100,000). Among participants
with a positive flexible sigmoidoscopic examination and no cancer detected on follow-up, there
were 19 perforations during 17,672 subsequent
diagnostic or therapeutic colonoscopic examinations (107.5 per 100,000). False positive results of
sigmoidoscopy, with no neoplasia identified at
subsequent diagnostic testing, were observed
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Table 4. Colorectal-Cancer Incidence and Mortality According to Location and Stage.
Variable

Cancer Stage
I

II

III

IV

Total
Carcinoid

Unknown

Flexible-sigmoidoscopy group
Cases of colorectal cancer — no.

334

Deaths from colorectal cancer — no. (%)

20 (6.0)

Cases of distal colorectal cancer — no.
Deaths from distal colorectal cancer — no. (%)

241

140

32

25

1012

70 (29.0)

113 (80.7)

3 (9.4)

20 (80.0)

252 (24.9)

202
11 (5.4)

Cases of proximal colorectal cancer — no.
Deaths from proximal colorectal cancer — no. (%)

240
26 (10.8)
110

96

41

24

6

479

15 (13.6)

28 (29.2)

33 (80.5)

0

0

87 (18.2)

131

130

9 (6.9)

145

96

8

2

512

42 (29.0)

78 (81.2)

3 (37.5)

0

143 (27.9)

309

328

209

9

25

1287

33 (10.7)

102 (31.1)

163 (78.0)

4 (44.4)

18 (72.0)

341 (26.5)

144

157

107

3

6

669
175 (26.2)

11 (8.5)

Usual-care group
Cases of colorectal cancer — no.

407

Deaths from colorectal cancer — no. (%)

21 (5.2)

Cases of distal colorectal cancer — no.
Deaths from distal colorectal cancer — no. (%)

252
14 (5.6)

25 (17.4)

50 (31.8)

84 (78.5)

1 (33.3)

1 (16.7)

153

164

170

98

6

4

595

7 (4.6)

8 (4.9)

52 (30.6)

77 (78.6)

3 (50.0)

0

147 (24.7)

Cases — no. (% reduction in incidence)

50 (19.8)

34 (23.6)

61 (38.9)

66 (61.7) −21 (−700.0)

0

190

Deaths — no. (% reduction in mortality)

3 (21.4)

10 (40.0)

22 (44.0)

51 (60.7)

1 (100.0)

1 (100.0)

88

Cases — no. (% reduction in incidence)

22 (14.4)

34 (20.7)

25 (14.7)

2 (2.0)

−2 (−33.3)

2 (50.0)

83

Deaths — no. (% reduction in mortality)

−2 (−28.6)

−3 (−37.5)

10 (19.2)

−1 (−1.3)

0

0

4

Cases of proximal colorectal cancer — no.
Deaths from proximal colorectal cancer — no. (%)
Between-group differences*
Distal colorectal cancer

Proximal colorectal cancer

* Differences in cases and deaths were calculated as the number in the usual-care group minus the number in the flexible-sigmoidoscopy
group. The percentage difference was calculated as 100 − [(flexible-sigmoidoscopy rate ÷ usual-care rate) × 100]. The flexible-sigmoidoscopy
rate was defined as cases in the flexible-sigmoidoscopy group divided by the flexible-sigmoidoscopy population, and the usual-care rate as
cases in the usual-care group divided by the usual-care population.

among 20% of men and 13% of women.27 Some of
the false positive sigmoidoscopic examinations
may have been due to false negative results of colonoscopy. Deaths from other causes, excluding
prostate, lung, colorectal, and ovarian cancers,
totaled 9138 (11.8%) in the intervention group and
9286 (12.0%) in the usual-care group (relative risk,
0.98; 95% CI, 0.96 to 1.01; P = 0.28) (Table S3 in
the Supplementary Appendix).

colonoscopy in the intervention group during the
screening phase by participants without a positive
screening examination was 5.5% (95% CI, 4.5 to
6.5). The rate of routine colonoscopy after the
screening phase was 47.7% (95% CI, 44.7 to 50.7) in
the intervention group and 48.0% (95% CI, 45.2 to
50.8) in the usual-care group.

Endoscopic Contamination

In this randomized study, flexible sigmoidoscopy,
as compared with usual care, was associated with
a 26% reduction in overall colorectal-cancer mortality and a 21% reduction in the incidence of
colorectal cancer. Mortality related to distal colorectal cancer was reduced by 50%, and the incidence
was reduced by 29%. A significant 14% reduction in

The estimated rate of endoscopic contamination in
the usual-care group during the screening phase
was 25.8% (95% CI, 23.6 to 28.0) for flexible sigmoidoscopy, 34.4% (95% CI, 32.0 to 36.8) for colonoscopy, and 46.5% (95% CI, 43.9 to 49.1) for either
flexible sigmoidoscopy or colonoscopy. The rate of
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the incidence of proximal colorectal cancer was observed, but there was no significant reduction in
mortality related to proximal cancer. The baseline
characteristics, rate and time of follow-up, treatment, and deaths according to cancer stage were
similar in the two study groups, findings that suggest similarities in the underlying risk, biologic features of the cancers, and treatment outcome. These
results provide strong support for the observed benefit as being directly attributable to sigmoidoscopic
screening.
The observed reductions in incidence and mortality are similar to the results of the United Kingdom11 and Italian12 studies of flexible sigmoidoscopy. Although the end results of these trials are
similar, there are notable differences among the
studies in enrollment criteria, compliance, screening frequency, and the use of endoscopic screening
outside the protocol. In the United Kingdom study,
a single flexible sigmoidoscopic screening for participants 55 to 64 years of age was performed. In
the PLCO trial, two screenings were offered, and
participants ranged from 55 to 74 years of age. In
the United Kingdom study, 71.2% of participants
underwent a screening examination, whereas in
the PLCO trial, 86.6% underwent at least one
screening. In the PLCO trial, the second screening increased the cumulative diagnostic yield of
cancer or advanced adenoma by 26% among
women and 34% among men.14 However, we cannot measure the incremental benefit of the second
examination on colorectal-cancer incidence or
mortality.
In the United States, endoscopic screening has
been widely endorsed,28,29 and population-based
data show an increase in use.30 We identified substantial use of flexible sigmoidoscopy and colonoscopy in the usual-care group during the time that
the intervention group was undergoing screening
and in both groups during follow-up after screening. This testing probably reduced the difference in
mortality and incidence between the two groups.
However, screening in the PLCO trial was performed primarily in the first study year, when
83.5% of participants were screened, whereas in
the usual-care group, testing accumulated over
time. In conjunction with the European trials,11,12
our study confirms that flexible sigmoidoscopy
substantially reduces colorectal-cancer incidence
and mortality, especially with regard to distal
colorectal cancer.
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Observational studies have raised doubts about
the benefit of endoscopic screening in reducing
mortality31,32 from and the incidence33,34 of proximal colorectal cancer. There is a lesser degree of
protection against cancer in the proximal colon
than in the distal colon.31-36 In the United Kingdom trial of flexible sigmoidoscopy, the benefit
with regard to colorectal-cancer incidence and
mortality was limited to the distal colon, but
only 5% of participants underwent colonoscopy.11 In the Italian study, 8.4% of participants
were referred for colonoscopy,12 and the reductions in the incidence of proximal colorectal
cancer (9%) and related mortality (15%) were not
significant. In the PLCO trial, we found a significant reduction in the incidence of proximal colorectal cancer. This effect was achieved with a colonoscopy rate of 21.9% as a direct effect of abnormal
screening results of flexible sigmoidoscopy, in
addition to colonoscopy occurring outside the
screening protocol and after the screening period. We did not observe a reduction in mortality related to proximal colorectal cancer. Much
of the benefit in reducing colorectal-cancer mortality from screening derives from a reduction in
stage IV disease,4 which has a much higher mortality than lower stages. In the PLCO trial, 79.1%
of participants with stage IV disease died of
colorectal cancer. For cancers in the distal colon, reductions of more than 60% in the incidence of stage IV disease and related mortality
were observed. In contrast, for cancers in the
proximal colon, no significant reductions in the
incidence of stage IV disease or related mortality
were identified. Furthermore, in the intervention
group, tumors that were not detected by screening were more likely to be proximal and at a
later stage than screening-detected tumors (Table 3).37
As compared with the distal colon, the proximal colon poses a more difficult challenge for
colorectal-cancer control because of limitations
in bowel preparation, a greater prevalence of advanced serrated adenomas, which are harder to
detect than conventional adenomas,38,39 and biologic differences, including a greater incidence of
BRAF mutation,39 microsatellite instability,38,40
and CpG island methylator phenotype (CIMP).40
Although our protocol was associated with a
reduction in the incidence of proximal colorectal
cancer, presumably because of the detection and
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removal of precursor adenomas that would otherwise have progressed to cancer, it apparently
did not succeed in identifying and successfully
removing a proportionally greater number of
precursor lesions destined to develop into fatal
colorectal cancers. We have estimated that using
colonoscopy rather than flexible sigmoidoscopy
as the screening method in the PLCO trial would
have increased the number of screening-detected
cancers by approximately 16 percentage points
(from <25% to approximately 40% of colorectal
cancers diagnosed in participants assigned to
flexible sigmoidoscopy) and that two thirds of
that increase would have been attributable to increased detection of proximal colorectal cancer.37 The effect on the incidence of proximal
colorectal cancer and related mortality of the
additional polyp removal with universal colonoscopy is not known.
The effectiveness of flexible sigmoidoscopy in
reducing mortality related to distal colorectal cancer reflects the reduction in cancer incidence, or
the reduced number of tumors that could have
resulted in death, and the identification of earlierstage tumors, which are less likely to cause
death than later-stage tumors. Screening-detected
cancers, though accounting for less than 25% of
tumors in the intervention group, were distinctly
and predominantly at an early stage (Table 3).37
Although the trial was not powered to detect
the effect of sigmoidoscopic screening on colorectal-cancer mortality and incidence in subgroups,
the results are suggestive of a stronger effect
among men than among women. This finding
may be due to the fact that women had a lower
proportion of screening-detected cancers (Table 3)
and a higher proportion of proximal colorectal
cancers than men.37 A significant differential effect between the screening of participants 55 to
64 years of age and those 65 to 74 years of age
was not observed.
Our results can be compared with those of the
Minnesota trial of fecal occult-blood testing. After 13 years of follow-up, with six rounds of fecal
occult-blood testing and a 38% rate of colonoscopy
in the annually screened group, colorectal-cancer
incidence was reduced by 12% (a nonsignificant
difference) and mortality by 33% (a significant
difference).41 In the PLCO trial, after a median
follow-up of 11.9 years with up to two flexible
sigmoidoscopic screenings in addition to screen-

n engl j med 366;25

ings outside the protocol in both groups, incidence
was reduced by 21% and mortality by 26%. Endoscopic testing appears to have a more potent
protective effect than fecal occult-blood testing in
reducing the incidence of colorectal cancer and
requires fewer rounds of testing, presumably because endoscopic testing detects more precursor
adenomas.7-9 However, whether endoscopic evaluation is a better screening test depends on the
population and available resources.
In conclusion, screening with flexible sigmoidoscopy, in conjunction with colonoscopy (predominantly) for diagnosis and management after
abnormal test results, was associated with a
significant and clinically important decrease in
colorectal-cancer incidence and mortality. The incidence of colorectal cancer was reduced in both
the distal and proximal colon. A significant reduction in mortality was observed only for cancer in
the distal colon.
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